Advertisement
Advertisement
Merck & Co., Inc. (MRCK34.SA)
São Paulo - São Paulo Delayed Price. Currency in BRL
Add to watchlist
At close: 04:54PM BRT
Advertisement
Loading interactive chart...
- Motley Fool
Why This Fast-Growing Dividend Stock Is a Buy
This could partly explain why the pharma stock Merck (NYSE: MRK) has rallied 21% year to date while the S&P 500 index has dropped 18% during that time. Last month, Merck reported results for the first quarter, ended March 31. For the quarter, Merck recorded $15.9 billion in net sales, which represented a 49.6% increase over the year-ago period.
- Zacks
Exelixis (EXEL) Announces Results From Phase II HNSCC Study
Exelixis (EXEL) phase II study evaluating Cabometyx in combination with Keytruda in patients with recurrent or metastatic head and neck squamous cell carcinoma meets primary goal.
- SELLAS Reports Preliminary Data Showing Clinical Benefit from Phase 1/2 Clinical Trial of Galinpepimut-S (GPS) in Combination with Keytruda® in Patients with WT1+ Advanced Ovarian CancerGlobeNewswire
- Data from SOTIO’s Phase 1/1b AURELIO-03 Trial of SOT101 Demonstrate Clinical Benefit in Patients with Solid TumorsGlobeNewswire
- Zacks
Pharma Stock Roundup: EU Nod for AZN, JNJ & Others, PFE COVID Jab Effective in Kids
European Commission authorizes a booster dose of AstraZeneca's (AZN) COVID-19 vaccine and approves Merck (MRK) and Roche's (RHHBY) oncology drugs for expanded use.
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
Advertisement
© 2022 Yahoo. All rights reserved.
